跳至主要内容
临床试验/NCT00292162
NCT00292162已完成不适用

Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure

NHS Greater Glasgow and Clyde1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2007年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
41
试验地点
1
主要终点
Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)

研究概览

简要总结

Heart failure is a condition that occurs when the heart muscle weakens and no longer contracts normally. Half of these patients have an irregularity of heart rhythm called atrial fibrillation (AF). Patients with both heart failure and AF spend more time in hospital, and die earlier than those with heart failure alone. AF is difficult to treat with conventional methods in patients with heart failure. Radiofrequency ablation is a new technique used to cure AF. The investigators aim to establish if radiofrequency ablation for atrial fibrillation in patients with advanced heart failure can result in marked improvement in the function of the heart.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent
  • Persistent atrial fibrillation (AF)
  • New York Heart Association (NYHA) II, III and IV chronic heart failure (CHF) despite optimal medical therapy for at least 3 months
  • left ventricular ejection fraction (LVEF) <35% - as measured by radionuclide ventriculography (RNVG)
  • Patients with CHF secondary to ischaemic and non-ischaemic aetiology

排除标准

  • QRS duration >150ms (or QRS 120-150 with evidence of mechanical cardiac dysynchrony)
  • Magnetic resonance imaging (MRI) - incompatible metallic (ferrous) prosthesis
  • Primary valvular disease as a cause of CHF
  • Reversible causes of CHF
  • Acute myocarditis
  • Patients aged 18 or less
  • Patients having undergone revascularisation procedures within 6 months
  • Paroxysmal AF
  • Pregnancy
  • Expected cardiac transplantation within 6 months

研究组 & 干预措施

medical therapy

Active Comparator

Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin

干预措施: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril (Drug)

medical therapy

Active Comparator

Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin

干预措施: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol (Drug)

medical therapy

Active Comparator

Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin

干预措施: Aldosterone Antagonists - spironolactone (Drug)

Radiofrequency ablation (RFA)

Active Comparator

Isolation of the pulmonary veins using radiofrequency ablation

干预措施: radiofrequency ablation (Procedure)

结局指标

主要结局

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)

时间窗: Baseline

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in %

Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%

时间窗: baseline and 6 months

left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time.

Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months

时间窗: 6 months

Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months

次要结局

  • Plasma B-type Natriuretic Peptide (BNP)(baseline and 6 months)
  • Plasma B-type Natriuretic Peptide (BNP) at Baseline(Baseline)
  • Plasma B-type Natriuretic Peptide (BNP) at 6 Months(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael MacDonald

Cardiology ST6

NHS Greater Glasgow and Clyde

研究点 (1)

Loading locations...

相似试验